newsfilter
← Latest News
GlobeNewswire·

NeuroOne Featured in New York Post on OneRF® Patient’s Remarkable Journey to Overcome Debilitating Facial Pain

NMTC
  • NeuroOne Medical Technologies Corporation highlighted a New York Post article featuring the successful treatment of Natisha "Tish" Long for trigeminal neuralgia using its FDA 510(k)-cleared OneRF Trigeminal Nerve Ablation System.
  • Ms. Long, a mother of four, became the first patient globally to undergo this specific ablation procedure at University Hospitals in Cleveland, Ohio, after failing to find relief from medications or prior invasive brain surgery.
  • The minimally invasive procedure, which lasted between 20 to 30 minutes, provided Ms. Long with immediate pain relief that persisted at the time of the article's publication on October 27, 2026.
  • NeuroOne's OneRF System allows physicians to test multiple nerve locations through a single probe insertion, eliminating the need for repeated repositioning required by conventional radiofrequency ablation probes.
  • CEO Dave Rosa stated that the company is expanding direct sales & distribution efforts to accelerate commercialization & broaden access to the OneRF Trigeminal Nerve Ablation System across the country.
  • NeuroOne markets a platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System, & the OneRF Trigeminal Nerve Ablation System.